Brooks Laboratories Limited

NSEI:BROOKS Stock Report

Market Cap: ₹4.2b

Brooks Laboratories Past Earnings Performance

Past criteria checks 0/6

Brooks Laboratories has been growing earnings at an average annual rate of 1.4%, while the Life Sciences industry saw earnings growing at 25.3% annually. Revenues have been growing at an average rate of 1.5% per year.

Key information

1.4%

Earnings growth rate

7.8%

EPS growth rate

Life Sciences Industry Growth11.2%
Revenue growth rate1.5%
Return on equity-33.5%
Net Margin-25.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Sep 28
Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Jun 10
Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Feb 22
Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Dec 08
Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Jul 07
Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Jan 05
Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Sep 22
Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Revenue & Expenses Breakdown

How Brooks Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:BROOKS Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24782-1991170
30 Jun 24817-1751080
31 Mar 24795-1961080
31 Dec 23745-1431090
30 Sep 23680-1541220
30 Jun 23618-1851440
31 Mar 23632-2091770
31 Dec 22790-2022090
30 Sep 22827-2182170
30 Jun 22865-2192070
31 Mar 22912-1131950
31 Dec 21778-2991800
30 Sep 21788-2581660
30 Jun 21872-1761540
31 Mar 21772-1941460
31 Dec 20815-1801450
30 Sep 20808-1831420
30 Jun 20653-2351390
31 Mar 20697-2441400
31 Dec 19660-1541430
30 Sep 19612-1491430
30 Jun 19612-1481260
31 Mar 19550-1481250
31 Dec 18544-1011260
30 Sep 18602-1061270
30 Jun 18592-1161270
31 Mar 18557-1381260
31 Dec 17555-1241140
30 Sep 17487-931030
30 Jun 17493-56880
31 Mar 1757517880
31 Dec 1663975830
30 Sep 1670798820
30 Jun 16774108770
31 Mar 16800106750
31 Dec 15828841470
30 Sep 15856731410
30 Jun 1586794490
31 Mar 1585295580
31 Dec 14805911390
30 Sep 14760881340
30 Jun 14796691260
31 Mar 14853721390
31 Dec 1388849910

Quality Earnings: BROOKS is currently unprofitable.

Growing Profit Margin: BROOKS is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BROOKS is unprofitable, but has reduced losses over the past 5 years at a rate of 1.4% per year.

Accelerating Growth: Unable to compare BROOKS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BROOKS is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (38.1%).

Return on Equity

High ROE: BROOKS has a negative Return on Equity (-33.54%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 03:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Brooks Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anil BurraFirstCall Research